Drugs / KPCXM18
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04629287 | Nov 2020 → Dec 2021 | — | Kunming Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07279493 | Nov 2025 → Oct 2026 expected | ischemic stroke | Kunming Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05745311 | Mar 2023 → May 2024 | ischemic stroke | Kunming Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KPCXM18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04629287 ↗ |
| Route | Intravenous | “Intravenous route” NCT04629287 ↗ |